24.2. Analysis.
Comparison 24 Topical calcineurin inhibitors: pimecrolimus 1% cream versus vehicle, Outcome 2 Primary: adverse events.
Comparison 24 Topical calcineurin inhibitors: pimecrolimus 1% cream versus vehicle, Outcome 2 Primary: adverse events.